Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
itacitinib (INCB039110)
i
Other names:
IBI 377, INCB039110, INCB-039110, INCB 39110, INCB39110, INCB-39110, INCB 039110, IBI-377, IBI377
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Incyte, Innovent Biologics
Drug class:
JAK1 inhibitor
Related drugs:
‹
ruxolitinib (73)
AZD1480 (5)
momelotinib (2)
DZD4205 (1)
tofacitinib (1)
INCB052793 (0)
SHR0302 (0)
ruxolitinib (73)
AZD1480 (5)
momelotinib (2)
DZD4205 (1)
tofacitinib (1)
INCB052793 (0)
SHR0302 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab + INCB039110
Sensitive: C3 – Early Trials
pembrolizumab + INCB039110
Sensitive
:
C3
pembrolizumab + INCB039110
Sensitive: C3 – Early Trials
pembrolizumab + INCB039110
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login